Aides and lobbyists expected the new draft proposal to focus more on surprise medical bills than on drug pricing. But its drug pricing policies particularly toward PBMs are surprisingly ambitious. httpsbuff.ly2M5mJvMÂ

Aides and lobbyists expected the new draft proposal to focus more on surprise medical bills than on drug pricing. But its drug pricing policies, particularly toward PBMs, are surprisingly ambitious. https://buff.ly/2M5mJvM 

Aides and lobbyists expected the new draft proposal to focus more on surprise medical bills than on drug pricing. But its drug pricing policies, particularly toward PBMs, are surprisingly ambitious. https://buff.ly/2M5mJvM 

More From BioPortfolio on "Aides and lobbyists expected the new draft proposal to focus more on surprise medical bills than on drug pricing. But its drug pricing policies, particularly toward PBMs, are surprisingly ambitious. https://buff.ly/2M5mJvM "